explain the association between depression and adverse outcomes in this population.
B I O C H E M I CA L M E C H A N I S M ( S ) U N D E R LY I N G D E P R E S S I O N : N I T R I C O X I D E , B R A I N -D E R I V E D N E U ROT RO P H I C FAC TO R A N D N E U R A L P L A S T I C I T Y
Mechanisms underlying the risks of depression are intensively investigated. The observation that altered serotonin levels are associated with enhanced platelet aggregation and vasoconstriction reveals a neural mechanism whereby depression can lead to coronary events in depressed patients in the general population [11] . Several lines of evidence point to nitric oxide (NO) dysregulation as a biological pathway involved in the high cardiovascular (CV) risk associated to depression. NO is involved in several major cellular functions including neurotransmission, regulation of blood vessel tone and immune response. In the central nervous system, NO participates in the regulation of synaptic plasticity [12] . NO interacts with many intracellular targets and is able to trigger an array of signal transduction pathways resulting in stimulatory or inhibitory output signals. Physiological amounts of NO are neuroprotective whereas an over-production of this gas is noxious [13] . Indeed, NO can undergo oxidative-reductive reactions to form cytotoxic compounds which in turn give rise to 'nitrosative stress', an alteration involved in major neurodegenerative disorders [14] . On the other hand, not only high but also low NO bioavailability is harmful for brain cells. In this respect, asymmetric dimethylarginine (ADMA), a major endogenous inhibitor of NO synthase, has been implicated in depressive disorders [15] . Depressive symptoms have indeed been associated with high ADMA levels and low L-arginine/ADMA ratio in patients with chronic hepatitis C infection [16] or heart failure [17] and in the elderly [18] . High ADMA is a hallmark of CKD [19] . Thus, this methylarginine is a plausible risk factor for CKD-associated depression. Emerging evidence suggests that interference of ADMA with mental functioning may depend on the effect of this methylarginine on a fundamental neurotrophin, the brain-derived neurotrophic factor (BDNF).
Experimental and clinical studies in depressed adults demonstrate altered neural plasticity including neuronal loss and a reduction in the total volume of the hippocampus [20] . BDNF is a critical mediator of neuronal plasticity in the developing and adult nervous system [21] . BDNF is a Janus molecule, its function being mediated by two specific receptors [i.e. tropomyosin-related kinase receptor B (TrKB) and pan75 neurotrophin receptor (p75 NTR )] which promote opposite effects on neuronal plasticity. BDNF-TrkB signalling stimulates neurogenesis, neurite arborization and synaptogenesis while BDNF-p75 signalling causes neurite retraction, neuronal apoptosis and synaptic pruning. The balance between the 'anabolic' and 'catabolic' effect of BDNF is central to optimizing the development and maintenance of neural networks. Decreased BDNF expression entails neurodegeneration and aberrant neuronal network function, and this neurotrophin is currently considered a likely player in depressive disorders [22] . A meta-analysis published in 2008 retrieved 20 studies including 1504 subjects investigating the link between BDNF and depression. In the aggregate analysis, BDNF levels increased significantly after antidepressant treatment, and BDNF levels and depression scores were significantly and inversely interrelated. The results of this meta-analysis were robust and were confirmed in sensitivity analyses with no evidence for publication bias [23] .
D E P R E S S I O N I N D I A LY S I S PAT I E N T S : A N A D M A A N D B D N F A F FA I R ?
In the current issue of Nephrology Dialysis and Transplantation, Jan Kielstein et al. [24] report an interesting pilot study exploring the role of ADMA and BDNF in depression in stage 5D (haemodialysis) CKD patients ( Figure 1) . The study includes a series of experiments in animal models and a small survey in a group of haemodialysis patients. The specific hypothesis tested in these studies is that high ADMA levels may induce depression by altering BDNF levels. Anxiety and locomotor activity in the rat were tested with the hole-board apparatus, an approach frequently applied in behavioural pharmacology studies. This apparatus consists of an enclosed board with regular, crossing lines delimiting quadratic areas each containing a hole at the centre. In this test, changes in head-dipping activity (into the holes of the board) are considered to reflect anxiety [25] . Subtotally (5/6) nephrectomized rats showed signs of major anxiety (time spent until first hole investigation) and decreased motor activity (number of lines crossed in a given time on the board). In this rat model of advanced renal insufficiency, the L-arginine/ADMA ratio was significantly lower than in the intact control rats, whereas plasma ADMA levels were only slightly higher than in the same control animals. Interestingly, immunohistochemistry studies in subtotally nephrectomized rats showed a reduced expression of hippocampal BDNF but similar plasma BDNF as compared with control rats. However, in ADMA-infused rats, serum BDNF levels were significantly lower than those observed in both 5/6 nephrectomized and control, intact rats. Overall observations by Kielstein et al. broadly implicate ADMA in depressive behavioural changes in the rat and suggest that BDNF may be the effector molecule conducive to depressive behaviour in this animal model of chronic renal insufficiency. Apparently, observations in rats coincided with findings in haemodialysis patients. Indeed, in a small series of 11 patients, serum BDNF was strongly associated in an inverse fashion with the severity of depression, as measured by Beck Depression Inventory (BDI). In general, experiments in rats and cross-sectional analyses in haemodialysis patients in this pilot study generate the fascinating hypothesis that ADMA, a compound which accumulates in end-stage renal disease and which has been associated with a variety of alterations, ranging from cardiovascular complications to several endocrine disturbances and bone disease [26] , is a major player in depression in these patients.
L I G H T S A N D S H A D E S O F T H E A D M A H Y P OT H E S I S O F D E P R E S S I O N I N C K D
This hypothesis-generating study has numerous weak points. First, the series of haemodialysis patients where the BDNF-BDI score relationship was tested is very small (n = 11), and the abstraction of this series from the source dialysis population is scarcely defined. Of note, the average age of this population was far lower than the average age of haemodialysis patients in Germany, and no information on comorbidities, an important potential confounder, was given. Thus, the very strong inverse relationship between BDNF levels and BDI (r = −0.81, shared variance = 65%) should to be confirmed in larger and better characterized series of haemodialysis patients. Furthermore, no evidence emerged in these cross-sectional analyses that BDNF could be the effector mechanism whereby ADMA may induce depression in these patients. A large amount of circulating BDNF is stored in platelets [27] , and serum BDNF levels are ∼200-fold higher than plasma levels [28] . Therefore, variations in serum BDNF levels may reflect changes in platelet release rather than changes in brain BDNF metabolism [29] , suggesting a distinct biological significance for serum and plasma BDNF. In the present study, both in patients and in rats, BDNF was measured in serum. Therefore, circulating BDNF in the present study hardly reflects brain BDNF. As to the experimental part of the present paper, the degree of internal coherence of findings in studies in the hole-board apparatus in rats was modest. For example, direct exploratory behaviour was reduced in 5/6 nephrectomized rats as compared with control rats but it was slightly above normal in intact, ADMA-infused rats, and an identical pattern emerged also for the 'hole investigation time' (a metric of anxiety). Thus, to date, ADMA per se fails to account for altered responses to hole-board testing in a model of advanced chronic renal insufficiency in the rat, and the putative ADMA-BDNF link in haemodialysis patients still remains unclear.
In conclusion, as it often occurs in exploratory investigations, in this pilot study by Kielstein et al. [24] there is light and shade, and perhaps the shade, rather than the light, still dominates the scene. Nonetheless, these stimulating observations may pave the way for a new series of experiments in animal models and observations in CKD and haemodialysis patients to investigate in depth the fascinating hypothesis that inhibition of the NO system by endogenous ADMA or other ADMA-dependent effects may be implicated in depressive disorders in CKD patients. Given the public health relevance of depression and CKD, future studies on this issue may produce fruitful knowledge for advancing the understanding of the complex link between these two major chronic disorders. 
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